Sign in

Cain A. Hayes

Director at DOCU
Board

About Cain A. Hayes

Independent Class II director at Docusign since December 2020; age 55. Former CEO of Point32Health (Jul 2021–Oct 2024) and Gateway Health Plan (Nov 2018–Jun 2021), with senior leadership roles at Blue Cross and Blue Shield of Minnesota and Aetna. Education: B.S. in Business Administration (Drake University), MBA (Webster University); Certified Employee Benefit Specialist (CEBS), Wharton School. Serves on Docusign’s Compensation and Leadership Development Committee; identified as independent under Nasdaq rules .

Past Roles

OrganizationRoleTenureCommittees/Impact
Point32Health (Harvard Pilgrim + Tufts Health Plan)Chief Executive OfficerJul 2021 – Oct 2024Led large health and well-being organization
Gateway Health PlanPresident & CEONov 2018 – Jun 2021Managed leading managed care organization
Blue Cross & Blue Shield of MinnesotaPresident & COO, Health BusinessApr 2017 – Nov 2018Operated health business; payer operations
AetnaPresident, National Accounts; other senior rolesNov 2010 – Mar 2017Grew complex national accounts; payer expertise
Nationwide Insurance; Principal Financial GroupSenior executive rolesPrior to 2010Financial services leadership

External Roles

  • No other public company directorships disclosed in Docusign’s proxy. Prior executive leadership roles noted above (not board roles) .

Board Governance

ItemDetail
Board classificationClassified board; Hayes is Class II (term through 2026 annual meeting)
IndependenceBoard determined Hayes is independent under SEC/Nasdaq standards
Committee assignmentsCompensation & Leadership Development Committee (member)
Committee chairsNone (Hayes is not a chair)
Board ChairIndependent Chair (Maggie Wilderotter)
AttendanceBoard held 24 meetings in FY25; each member attended ≥75% of Board/committee meetings for which they served
EvaluationsAnnual Board/committee self-evaluations overseen by Nominating Committee
InterlocksNo compensation committee interlocks; no insider participation

Fixed Compensation (Director)

ComponentFY25 AmountNotes
Cash fees (Hayes)$57,900 Reflects base retainer and committee member fees
Standard cash retainer$46,500 Paid quarterly; pro-rated for partial service
Committee member fee (Compensation)$11,400 Non-chair member fee
Other committee feesAudit member $15,000; Nominating member $6,000; Chair fees vary (Audit $30,000; Compensation $22,500; Nominating $12,200)

Performance Compensation (Director)

Equity ComponentFY25 Amount/StructureVestingChange-in-Control
Annual RSU grant (Hayes)$249,971 grant-date fair value Vests in four quarterly installments; final installment by next annual meeting or 1-year from grant Annual grants vest in full upon change-in-control
Outstanding RSUs (as of 1/31/25)2,137 units Quarterly vesting per policy As above

Directors at Docusign receive time-based RSUs; no PSUs/options are part of standard non-employee director equity grants (Hayes has no disclosed options) .

Other Directorships & Interlocks

CategoryDetail
Current public company boardsNone disclosed beyond Docusign
Committee interlocksNone; no reciprocity with other companies’ boards/comp committees
Related-party transactionsNone involving Hayes disclosed; company noted a related OneNotary transaction connected to director Peter Solvik/JSV, not Hayes

Expertise & Qualifications

QualificationEvidence
Senior leadership in healthcare/financial servicesCEO roles at Point32Health; Gateway Health; senior Aetna leadership
Finance and riskSkills matrix flags Finance, Risk Management
Cyber/Info security awarenessSkills matrix flags Cybersecurity/Information Security
Corporate governanceSkills matrix flags Corporate Governance
Education & credentialsB.S. (Drake), MBA (Webster), CEBS (Wharton)

Board skills matrix does not mark Hayes for “Public Board Member Experience,” suggesting limited prior public board roles pre-Docusign; nonetheless he serves as an independent director with relevant sector expertise .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingNotes
Cain A. Hayes11,732<1%As of March 15, 2025; includes direct/indirect per proxy
Outstanding RSUs (director)2,137As of January 31, 2025

Stock ownership guidelines require non-employee directors to hold equity equal to 3x the Board retainer; company disclosure states all directors either have met guidelines or have time remaining to comply under the 5-year window .

Governance Assessment

  • Board effectiveness: Hayes contributes sector expertise (healthcare/financial services), finance, risk, and cybersecurity skills; independent status and Compensation Committee service support oversight of pay and human capital policies .
  • Alignment & incentives: Director pay mix is heavily equity-based (FY25 stock awards $249,971 vs cash $57,900), promoting alignment; RSUs accelerate on change-in-control (market standard). Ownership guidelines (3x retainer) strengthen alignment; Hayes holds 11,732 shares and 2,137 outstanding RSUs .
  • Conflicts/related party exposure: No Hayes-related transactions disclosed; compensation committee interlocks absent; insider trading policy prohibits hedging/pledging, reducing misalignment risk .
  • Engagement/attendance: Company reports ≥75% attendance for all directors; independent Chair structure enhances oversight; annual evaluations in place .
  • Broader governance signals: Say-on-Pay support improved from ~16% (2023) to ~45% (2024), with continued shareholder engagement and program changes; while not specific to Hayes, as a Compensation Committee member he is part of the oversight contributing to responsiveness .

RED FLAGS: None identified specific to Hayes in FY25 disclosures. Company-wide items to monitor include classified board structure (Board defends as appropriate for size/tenure/industry) and historically low say-on-pay (improving but below typical support), which could draw investor scrutiny; Hayes’ role on the Compensation Committee makes ongoing responsiveness important .

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%